tbuckley/cabot-search huggingface dataset:
Emerging collaborative research platforms for the next generation of physical activity, sleep and exercise medicine guidelines: the Prospective Physical Activity, Sitting, and Sleep consortium (ProPASS)
Authors: Emmanuel Stamatakis, Annemarie Koster, Mark Hamer, Vegar Rangul, I-Min Lee, Adrian E Bauman, Andrew J Atkin, Mette Aadahl, Charles E Matthews, Paul Jarle Mork, Lisa Askie, Peter Cistulli, Malcolm Granat, Peter Palm, Patrick Joseph Crowley, Matthew Stevens, Nidhi Gupta, Anna Pulakka, Sari Stenholm, Daniel Arvidsson, Gita Mishra, Patrik Wennberg, Sebastien Chastin, Ulf Ekelund, Andreas Holtermann
Journal: British Journal of Sports Medicine (2019)

Emerging collaborative research platforms for the next generation of physical activity, sleep and exercise medicine guidelines : the Prospective Physical Activity, Sitting, and Sleep consortium (ProPASS)
SAT-358-Sodium glucose cotransporter 2 inhibitor, canagliflozin ameliorate liver function in Japanese patients with type 2 diabetes mellitus: Subgroup analyses of clinical trials
Authors: Yuya Seko, Yoshio Sumida, Kazuyo Sasaki, Yoshito Itoh, Hiroaki Iijima, Toshio Hashimoto, Shinichi Ishii, Nobuya Inagaki
Journal: Journal of Hepatology (2019)
THU-007-Absence of BSEP (ABCB11) protects MDR2 (ABCB4) KO mice from cholestatic liver and bile duct injury through anti-inflammatory bile acid composition and signaling
Authors: Claudia Fuchs, Veronika Mlitz, Matteo Tardelli, Jelena Remetic, Moritz Menz, Gustav Paumgartner, Susanne Wolfrum, Annika Wahlström, Marcus Ståhlman, Tatjana Stojakovic, Christian Wolfrum, Hanns-Ulrich Marschall, Michael Trauner
Journal: Journal of Hepatology (2019)
Impact of underlying pulmonary diseases on treatment outcomes in early stage non-small cell lung cancer treated with definitive radiotherapy
Authors: H. Kim, H. Yoo, H. Pyo, H.Y. Park
Journal: Annals of Oncology (2019)

Background: Current guidelines recommend definitive radiotherapy for patients with medically inoperable early stage non-small cell lung cancer (NSCLC). However, impact of underlying pulmonary diseases on survival of those patients are unclear. Especially, although the patients with COPD and lung cancer have worse prognosis than those without COPD regardless tumor stage, the impact of coexisting COPD on treatment outcome after definitive radiotherapy has not been fully investigated. Thus, we aimed to evaluate the impact of underlying chronic pulmonary disease of COPD, IPF, and CPFE on treatment outcome following definitive radiotherapy in patients with medically inoperable stage I-II NSCLC. Methods: We retrospectively reviewed the medical records of 234 patients with stage I-II NSCLC treated with definitive radiotherapy alone at Samsung Medical Center, between January 2010 and October 2017. We compared the survival outcomes according to the presence of underlying pulmonary diseases of chronic obstructive pulmonary disease (COPD), combined pulmonary fibrosis and emphysema (CPFE), and idiopathic pulmonary fibrosis (IPF). In current study, we defined control group as non-COPD, non-CPFE, and non-IPF. Results: Among 234 study patients, 132 (56.4%) were diagnosed with COPD, 16 (6.8%) with CPFE, and 22 (9.4%) with IPF. The median follow-up duration was 17 months (range, 1 to 92 months). The median survival of control, COPD, CPFE, and IPF groups were 32, 49, 17, and 12 months, respectively (P < 0.001). In a Cox proportional hazards analysis for factors associated with overall survival, patients with COPD showed similar risk of death (Adjusted HR, 1.314; 95% CI, 0.677-2.551; p-value= 0.419) compared to control group, while patients with IPF (Adjusted HR, 3.539; 95% CI, 1.647-7.607; p-value= 0.001) and CPFE (Adjusted HR, 2.669; 95% CI, 1.095-6.505; p-value= 0.031) showed increased risk of death. Conclusions: Definitive radiotherapy may be a tolerable treatment for early-stage NSCLC with COPD. However, the poor survival in early-stage NSCLC patients with co-existing IPF or CPFE warrants further study to identify and develop patient selection criteria and optimal radiotherapy modality. Legal entity responsible for the study: The authors. Funding: Has not received any funding. Disclosure: All authors have declared no conflicts of interest.
Impact of thrombocytosis and neutrophil-to-lymphocyte ratio before start of chemoradiotherapy on patient survival in inoperable stage III NSCLC
Authors: M. Hoffmann, J. Taugner, O. Roengvoraphoj, C. Eze, L. Käsmann, C. Belka, F. Manapov
Journal: Annals of Oncology (2019)

Background: We aimed to evaluate an impact of thrombocytosis and neutrophil-to-lymphocyte ratio (NLR) before start of multimodal treatment on survival of patients with inoperable locally advanced non-small cell lung cancer (NSCLC). Methods: Retrospective data of 99 patients (ECOG 0-1) with inoperable NSCLC stage III receiving definitive chemoradiotherapy (CRT) between 2010 and 2016 at our institute were analyzed. Complete blood count and neutrophil- to- lymphocyte ratio (NLR) before initiation of multimodal treatment were evaluated and correlated with EFS and OS. Results: The median age was 67 years and 63 % of patients were male. Median follow-up for the entire cohort was 17 months (range: 2 – 92). Patients with initial thrombocytosis (>401 x 109/L) demontrated a significantly shorter median EFS (7 vs. 14.5 months, p < 0.001, log-rank test) and OS (11 vs. 23 months, p = 0.002, log-rank test) vs. patients with normal platelet count. Patients with NLR >3.5 before start of multimodal treatment had a significantly worse prognosis than patients with lower initial NLR (0.78 – 3.5), (17.2 vs 29.3 months, p = 0.041, log-rank test). Conclusions: Initial thrombocytosis and NLR > 3.5 were associated with shorter survival in patients with inoperable stage III NSCLC treated with definitive CRT. Legal entity responsible for the study: The authors. Funding: Has not received any funding. Disclosure: All authors have declared no conflicts of interest.
Children under 10 years of age were more affected by the 2018/19 influenza A(H1N1)pdm09 epidemic in Canada: ‎possible cohort effect following the 2009 influenza pandemic
Authors: Danuta M Skowronski, Siobhan Leir, Gaston De Serres, Michelle Murti, James A Dickinson, Anne-Luise Winter, Romy Olsha, Matthew A Croxen, Steven J Drews, Hugues Charest, Christine Martineau, Suzana Sabaiduc, Nathalie Bastien, Yan Li, Martin Petric, Agatha Jassem, Mel Krajden, Jonathan B Gubbay
Journal: Eurosurveillance (2019)

IntroductionFindings from the community-based Canadian Sentinel Practitioner Surveillance Network (SPSN) suggest children were more affected by the 2018/19 influenza A(H1N1)pdm09 epidemic.AimTo compare the age distribution of A(H1N1)pdm09 cases in 2018/19 to prior seasonal influenza epidemics in Canada.MethodsThe age distribution of unvaccinated influenza A(H1N1)pdm09 cases and test-negative controls were compared across A(H1N1)pdm09-dominant epidemics in 2018/19, 2015/16 and 2013/14 and with the general population of SPSN provinces. Similar comparisons were undertaken for influenza A(H3N2)-dominant epidemics.ResultsIn 2018/19, more influenza A(H1N1)pdm09 cases were under 10 years old than controls (29% vs 16%; p < 0.001). In particular, children aged 5-9 years comprised 14% of cases, greater than their contribution to controls (4%) or the general population (5%) and at least twice their contribution in 2015/16 (7%; p < 0.001) or 2013/14 (5%; p < 0.001). Conversely, children aged 10-19 years (11% of the population) were under-represented among A(H1N1)pdm09 cases versus controls in 2018/19 (7% vs 12%; p < 0.001), 2015/16 (7% vs 13%; p < 0.001) and 2013/14 (9% vs 12%; p = 0.12).ConclusionChildren under 10 years old contributed more to outpatient A(H1N1)pdm09 medical visits in 2018/19 than prior seasonal epidemics in Canada. In 2018/19, all children under 10 years old were born after the 2009 A(H1N1)pdm09 pandemic and therefore lacked pandemic-induced immunity. In addition, more than half those born after 2009 now attend school (i.e. 5-9-year-olds), a socio-behavioural context that may enhance transmission and did not apply during prior A(H1N1)pdm09 epidemics.
Abstract 16932: Local Production of Interleukin-33 and its Ability to Activate Mast Cells to Produce Pro-fibrotic Mediators May be Associated With Cardiac Fibrosis
Authors: Stephanie A Legere, Jean S Marshall, Jean-François Légaré
Journal: Circulation (2016)

Introduction: Cardiac fibrosis is a complex process in which inflammation is a key component. Mast cells are innate immune sentinel cells found in multiple tissues, including the heart and often as...
When suspicions turn to real evidence
Authors: Tom Moberly
Journal: BMJ (2019)

Clinical studies sometimes surprise us, upturning conventional wisdom and forcing us to rethink our understanding of a condition. At other times they can disappoint, when promising treatments turn out not to have any real benefits for patients.

A study reported this week (doi:10.1136/bmj.l1255) fits another tradition: supporting and quantifying a link that has long been suspected to exist but for which evidence has proved hard to find. In this case, the …
Non-Small Cell Lung Cancer (NSCLC) harboring Epidermal Growth Factor Receptor mutations (EGFR-m) and breast cancer (BC): A retrospective analysis of a single institution.
Authors: Teresa Moran, Vanesa Quiroga, Enric Carcereny Costa, Beatriz Cirauqui, Mireia Margeli, Laia VilÃ Martinez, Maria de los Llanos GIL Gil Moreno, Alberto Indacochea, Jose Luis Cuadra Urteaga, Cristina Queralt, Itziar de Aguirre, Jose Luis Ramirez, Eva Castella, Yessica Lopez, Jose Luis Mate, Rafael Rosell
Journal: Journal of Clinical Oncology (2015)

e19112 Background: EGFR-m in NSCLC and its responsiveness to TKI has proved beneficial in a subset of NSCLC patients (p) Breast cancer (BC) represents the most incident neoplasm among women. The co-existence of both EGFR-m-NSCLC and BC has been reported in p with Li-Fraumeni Syndrome. However, no systematic evaluation of the presence of both types of cancers has been performed in the general population. Methods: We sought to evaluate if EGFR-m-NSCLC associates higher rates of 2nd BC than the EGFR-wild type (WT)p. Clinical and molecular characteristics, as well as clinical outcomes of female p visited at our Institution from 2008 to 2014 and harboring both types of tumors were registered. Results: 69/578 female p with EGFR-m were identified. Data on treatment and follow-up of 62p were available. 11/ 62p (17.7%) were diagnosed with both EGFR-m-NSCLC and BC. For EGFR-m-W-p, BC was diagnosed in 3 cases (0.52%) Regarding EGFR-m-NSCLC, age of diagnosis was 65y; 100% of p were Caucasian and never smokers. Del19, L858 and L861Q represented the 72.7%, 27.3% and 9% of EGFR-m. 36.3% had stage IV, 27.2% recurred after surgery and 36.3% initial stages never recurred. 63.6% received a TKI (42.8% erlotinib). 85.7% received TKI as 1st line. The overall response rate was 85.7%. 42.8% received subsequent therapies. The cause of death was related to lung cancer in all cases of death (54.5%). mOS was 29 months from the time of LC diagnosis. Regarding BC, the median age of diagnosis was 52y, BC was a prior diagnosis in 90.9%; the stage was 0, I, IIA and IIIA in 18.18%, 27.27%, 45.45% and 9.09%, respectively. After surgery (100%), 36.36% received ET, 36.36% both chemotherapy and ET and 54.54% radiotherapy (RT). 83.33% of p treated with RT developed the LC in the RT field. 90.90% of p never recurred. Conclusions: Diagnosis of BC appears to be higher in EGFR-m-NSCLC-p than in the general population. Evaluation of the molecular mechanism potentially related to this association is warranted.
Phase III Trial: Adjuvant Pelvic Radiation Therapy Versus Vaginal Brachytherapy Plus Paclitaxel/Carboplatin in High-Intermediate and High-Risk Early-Stage Endometrial Cancer
Authors: Marcus E. Randall, Virginia Filiaci, D. Scott McMeekin, Vivian von Gruenigen, Helen Huang, Catheryn M. Yashar, Robert S. Mannel, Jae-Weon Kim, Ritu Salani, Paul A. DiSilvestro, James J. Burke, Thomas Rutherford, Nick M. Spirtos, Keith Terada, Penny R. Anderson, Wendy R. Brewster, William Small, Carol A. Aghajanian, David S. Miller
Journal: Journal of Clinical Oncology (2019)

The primary objective was to determine if vaginal cuff brachytherapy and chemotherapy (VCB/C) increases recurrence-free survival (RFS) compared with pelvic radiation therapy (RT) in high-intermediate and high-risk early-stage endometrial carcinoma.
Evaluation for Fibrosis After Cure of Hepatitis C—Reply
Authors: Julius Wilder, Steve S. Choi, Cynthia A. Moylan
Journal: JAMA (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
THU-225-Risk prediction model for hepatocellular carcinoma after hepatitis b e antigen seroclearance in patients treated with entecavir or tenofovir
Authors: Tae Seop Lim, Mi Young Jeon, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Kwang-Hyub Han, Seung Up Kim
Journal: Journal of Hepatology (2019)
Highly bright and stable NIR-BRET with blue-shifted coelenterazine derivatives for deep-tissue imaging of molecular events <i>in vivo</i>
Authors: Ryo Nishihara, Ramasamy Paulmurugan, Takahiro Nakajima, Eiji Yamamoto, Arutselvan Natarajan, Rayhaneh Afjei, Yuki Hiruta, Naoko Iwasawa, Shigeru Nishiyama, Daniel Citterio, Moritoshi Sato, Sung Bae Kim, Koji Suzuki
Journal: Theranostics (2019)

Background: Bioluminescence imaging (BLI) is one of the most widely used optical platforms in molecular imaging, but it suffers from severe tissue attenuation and autoluminescence in vivo.Methods: Here, we developed a novel BLI platform on the basis of bioluminescence resonance energy transfer (BRET) for achieving a ∼300 nm blue-to-near infrared shift of the emission (NIR-BRET) by synthesizing an array of 18 novel coelenterazine (CTZ) derivatives, named "Bottle Blue (BBlue)" and a unique iRFP-linked RLuc8.6-535SGfusion protein as a probe.Results: The best NIR-BRET was achieved by tuning the emission peaks of the CTZ derivatives to a Soret band of the iRFP.In mammalian cells, BBlue2.3,one of the CTZ derivatives, emits light that is ∼50-fold brighter than DBlueC when combined with RLuc8.6-535SG, which shows stable BL kinetics.When we used a caged version of BBLue2.3, it showed a BL half decay time of over 60 minutes while maintaining the higher signal sensitivity.This NIR BL is sufficiently brighter to be used for imaging live mammalian cells at single cell level, and also for imaging metastases in deep tissues in live mice without generating considerable autoluminescence.A single-chain probe developed based on this BLI platform allowed us to sensitively image ligand antagonist-specific activation of estrogen receptor in the NIR region. Conclusion:This unique optical platform provides the brightest NIR BLI template that can be used for imaging a diverse group of cellular events in living subjects including protein-protein interactions and cancer metastasis.
Targeting a Pre-existing Anti-transgene T Cell Response for Effective Gene Therapy of MPS-I in the Mouse Model of the Disease
Authors: Giorgia Squeri, Laura Passerini, Francesca Ferro, Cecilia Laudisa, Daniela Tomasoni, Federica Deodato, Maria Alice Donati, Serena Gasperini, Alessandro Aiuti, Maria Ester Bernardo, Bernhard Gentner, Luigi Naldini, Andrea Annoni, Alessandra Biffi, Silvia Gregori
Journal: Molecular Therapy (2019)

Mucopolysaccharidosis type I (MPS-I) is a severe genetic disease caused by a deficiency of the alpha-L-iduronidase (IDUA) enzyme. Ex vivo hematopoietic stem cell (HSC) gene therapy is a promising therapeutic approach for MPS-I, as demonstrated by preclinical studies performed in naive MPS-I mice. However, after enzyme replacement therapy (ERT), several MPS-I patients develop anti-IDUA immunity that may jeopardize ex vivo gene therapy efficacy. Here we treat MPS-I mice with an artificial immunization protocol to mimic the ERT effect in patients, and we demonstrate that IDUA-corrected HSC engraftment is impaired in pre-immunized animals by IDUA-specific CD8+ T cells spared by pre-transplant irradiation. Conversely, humoral anti-IDUA immunity does not impact on IDUA-corrected HSC engraftment. The inclusion of lympho-depleting agents in pre-transplant conditioning of pre-immunized hosts allowes rescue of IDUA-corrected HSC engraftment, which is proportional to CD8+ T cell eradication. Overall, these data demonstrate the relevance of pre-existing anti-transgene T cell immunity on ex vivo HSC gene therapy, and they suggest the application of tailored immune-depleting treatments, as well as a deeper immunological characterization of patients, to safeguard the therapeutic effects of ex vivo HSC gene therapy in immunocompetent hosts.
PS-177-HSD17B13 rs72613567 TA is associated with a reduced risk for developing hepatocellular carcinoma in patients with alcohol-related cirrhosis
Authors: Felix Stickel, Philipp Lutz, Stephan Buch, Janett Fischer, Vanessa Rausch, Ines Silva, Jonas Rosendahl, Hans Dieter Nischalke, Marcin Krawczyk, Frank Lammert, Markus Casper, Steffen Zopf, Silke Marhenke, Arndt Vogel, Florian Eyer, Johann von Felden, Daniel Gotthardt, Karl Heinz Weiss, Ulrich Spengler, Sebastian Mueller, Ali Canbay, Guido Alessandro Baselli, Luca Valenti, Andrew McQuillin, Thomas Berg, Jochen Hampe, Marsha Morgan
Journal: Journal of Hepatology (2019)
P2.04-006 ADAURA: PhIII, Double-Blind, Randomized Study of Osimertinib vs Placebo in EGFR Mutation-Positive NSCLC Post-Tumor Resection
Authors: R. Herbst, Y. Wu, H. Mann, Y. Rukazenkov, M. Marotti, M. Tsuboi
Journal: Journal of Thoracic Oncology (2017)
THU0245 Early inflammatory arthritis clinics. do we need new diagnostic criteria?
Authors: G Salvador, R Sanmartí, JD Cañete, A Gómez, JR Rodriguez, D Cerdá, J Muñoz-Gómez
Journal: Annals of the Rheumatic Diseases (2001)

<h3>Background</h3> The usefulness of the diagnostic criteria for RA (ARA 1987) and spondyloarthropathy (European Group for Spondyloarthropaties 1993) in early inflammatory arthritis remains controversial. <h3>Objectives</h3> To analyse the prevalence of inflammatory arthritis according to different diagnostic cathegories, in an early arthritis clinic. <h3>Methods</h3> We recruited during one year period (Jan/00-Jan/01) 62 patients (38F, 24M) mean age 48 ys (range 17–79 ys), and mean disease duration of 3,1 m (range 2 wks- 12 m). All patients had objective sinovitis in one or more joints with a disease duration between 2 weeks and one year. Septic arthritis and crystal deposition disease have been excluded. Poliarthritis was seen in 37 patients, oligoarthritis in 18 and monoarthritis in 7. At the time of inclusion 20 out of 62 patients fulfilled ARA (1987) criteria for RA (mean disease duration 4 m), 4 patients fulfilled European Group for Spondyloarthopathies criteria (mean disease duration 2 m), 2 patients had psoriatic arthritis (mean disease duration 5 m), 9 had self-limited arthritis (mean disease duration 3 weeks), in 4 of them an acute infection by PVB19 have been found. In 25 patients arthritis was considered unclassified (mean time disease duration 3 m). After a mean time follow-up of 6 months (3w-1 yr) 14 out of 20 patients of RA group still fulfilled RA criteria (70%), the other six fulfilled criteria for different diseases (2 Sjögren sindrome, 1 RS3PE, 1 Polymyalgia, 1 self-limited arthritis and 1 mixed connective tissue disease. Among unclassified arthritis group, 5/25 fulfilled RA criteria and 6/25 patients had oligoarthritis with HLA-B27+ which could suggest a probably spondyloarthropathy despite they didn?t fulfil European Group criteria. Other 3/25 patients developed: 1 Sjögren syndrome, 1 self-limited arthritis and 1 olygoarthritis ANA+ with Hashimoto?s thyroyditis. <h3>Results</h3> <h3>Conclusion</h3> Present diagnostic criteria for RA, have limited sensitivity and specificity to correctly classify early inflammatory arthritis. Some patients with unclassified arthritis probably have a spondyloarthropathy although they don?t fulfilled the European Group criteria. The development of new diagnostic criteria in patients with early arthritis is necessary.
Unmet needs in lung cancer: Preliminary data analysis of comparison between caregivers, oncologists, nurses, and patient’s perceptions from a national multicenter study (E-LUNG).
Authors: Riccardo Torta, Mario Airoldi, Marcello Tiseo, Enrico Cortesi, Milena Vitali, Gianpiero Fasola, Carmelo Iacono, Alessandro Morabito, Rossana Berardi
Journal: Journal of Clinical Oncology (2015)

e20590 Background: Different types of measures have been developed in an attempt to assess cancer patients’ well-being. The aim of this study was to determine the prevalence and predictors of the perceived unmet needs of lung cancer patients, comparing the perception of their caregivers, oncologists and nurses in a national multicenter study. Methods: e-LUNG used a cross-sectional multicenter methodology and a self-assessment procedure. 1184 between lung cancer patients, caregivers, oncologists and nurses were interviewed to evaluate their perceived needs inherent to have lung cancer (LCN). Patients were also asked to complete the Hospital Anxiety and Depression Scale to assess their level of anxious-depressive symptomatology. To study the predictive power of LCN to the patients’ levels of anxious-depressive symptomatology, binary logistic regression model (M1) was performed. Results: M1 was statistically significant (χ2(6) = 61.688, p < 0.001) and showed a good fit (χ2HL(8) = 13.307, p = 0.101). The Nagelkerke R-square (pseudo R2 = 0.404) indicated the M1 accounted for the 40% of the total variance. The overall hit rate was 78.9%, an increase of 29% if compared to the percentage of correct classification by chance. The Wald statistic showed that psychological unmet needs (Exp(B) = 1.074) and unmet needs related to lung cancer symptoms (Exp(B) = 1.192) were statistically significant predictors. For each nine points increase in the level of psychological unmet needs there was a 1.89 times greater likelihood of being anxious-depressed. For each three points increase in the level of unmet needs related to lung cancer symptoms there was a 1.69 times greater likelihood of being anxious-depressed. Conclusions: Findings from e-LUNG study confirm a significant link between specific unmet needs related to cancer and the development of anxious-depressive symptomatology and suggest that these lacks in cancer care should be taken into account to foster wellbeing in patients.